Buscopan Compositum ad us.vet. 4 mg/ml + 500 mg/ml, solution injectable pour chevaux, veaux et chiens

Authorised

- Hyoscine butylbromide
- Metamizole sodium

Product identification

Medicine name:
Buscopan Compositum ad us.vet. 4 mg/ml + 500 mg/ml, solution injectable pour chevaux, veaux et chiens
Buscopan Compositum ad us. vet. 4 mg/ml + 500 mg/ml, Injektionslösung für Pferde, Kälber und Hunde

Active substance:
Hyoscine butylbromide
Metamizole sodium

Target species:
Cattle
Cattle (calf)
Horse
Dog

Route of administration:
Intravenous use
Subcutaneous use

Product details

Active substance and strength:
Hyoscine butylbromide
4.00 milligram(s) / 1.00 millilitre(s)

Metamizole sodium
500.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:
Intravenous use:

- **Cattle**
  - Milk. no withdrawal period

Not to be used in animals producing milk for human consumption

- **Cattle (calf)**
  - Meat and offal. 15 day

- **Horse**
  - Meat and offal. 12 day
  - Milk. no withdrawal period

Not to be used in animals producing milk for human consumption

- **Dog**

Subcutaneous use:

- **Cattle**

- Milk. no withdrawal period

Not to be used in animals producing milk for human consumption

- **Cattle (calf)**
  - Meat and offal. 15 day
- **Horse**
  - Meat and offal. 12 day
  - Milk. no withdrawal period

Not to be used in animals producing milk for human consumption

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QA03BB01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Luxembourg

Available in:
Luxembourg

Package description:
Buscopan Compositum ad us. vet 1 Vial of 100 ml with Solution for injection

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:
31/12/1991

Manufacturing sites for batch release:
Labiana Life Sciences S.A.

Responsible authority:
Ministry Of Health

Authorisation number:
V 642/97/11/0345

Date of authorisation status change:
16/03/2010

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
